New drug aims to ease daily struggles of myasthenia gravis

NCT ID NCT07647510

Recruiting now Disease control Sponsor: Dianthus Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether claseprubart (DNTH103) can improve symptoms of generalized myasthenia gravis, a condition causing muscle weakness. About 195 adults with a specific antibody type are randomly assigned to receive the drug or a placebo. The main goal is to see if the drug helps with daily activities and muscle strength over 17 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: claseprubart (DNTH103)
What this could lead to: If successful, this could provide a new treatment option for people with generalized myasthenia gravis, potentially improving their ability to perform daily activities and muscle strength.
What could go wrong: This is a phase 3 trial, but results may not confirm benefit or could show side effects. The drug is still investigational and not yet approved.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS, GENERALIZED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYASTHENIA GRAVIS, GENERALIZED

Contacts and locations

Locations

Cinical Study Site
RECRUITING

Fayetteville, North Carolina, 28304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.